Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week DDW 2023 for REBYOTA fecal microbiota live jslm a firstinclass singledose microbiomebased treatment approved by the U.S. Food and Drug Administration FDA for the prevention of recurrent C. difficile C. diff infection in individuals 18 years of age and older following antibiotic treatment for recurrent C. diff infection.